Omadacycline successfully treated severe pneumonia after moxifloxacin treatment failure: Case series.

is a significant pathogen responsible for community-acquired pneumonia and, less commonly, for hospital-acquired pneumonia. , the most prevalent species within the genus, accounts for 80%-90% of human infections, and often leads to severe pneumonia complicated by multi-organ dysfunction. Omadacycline, a novel tetracycline, has demonstrated activity against atypical pathogens, including ; however evidence regarding its application in severe pneumonia remains limited. In this paper, we report 3 cases of successful treatment of severe pneumonia with omadacycline in patients who initially did not respond to empirical treatment with moxifloxacin, aiming to provide clinical experience and guidance for the use of omadacycline.